VEGF	NN
ameliorates	VBZ
pulmonary	JJ
hypertension	NN
through	IN
inhibition	NN
of	IN
endothelial	JJ
apoptosis	NN
in	IN
experimental	JJ
lung	NN
fibrosis	NN
in	IN
rats	NNS
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
can	MD
lead	VB
to	TO
the	DT
development	NN
of	IN
secondary	JJ
pulmonary	JJ
hypertension	NN
(	(
PH	NN
)	)
and	CC
ultimately	RB
death	NN
.	.

Despite	IN
this	DT
known	JJ
association	NN
,	,
the	DT
precise	JJ
mechanism	NN
of	IN
disease	NN
remains	VBZ
unknown	JJ
.	.

Using	VBG
a	DT
rat	NN
model	NN
of	IN
IPF	NN
,	,
we	PRP
explored	VBD
the	DT
role	NN
of	IN
the	DT
proangiogenic	JJ
and	CC
antiapoptotic	JJ
growth	NN
factor	NN
VEGF	NN
in	IN
the	DT
vascular	JJ
remodeling	NN
that	WDT
underlies	VBZ
PH.	NNP
In	IN
this	DT
model	NN
,	,
adenoviral	JJ
delivery	NN
of	IN
active	JJ
TGF-beta1	NN
induces	VBZ
pulmonary	JJ
arterial	JJ
remodeling	NN
,	,
loss	NN
of	IN
the	DT
microvasculature	NN
in	IN
fibrotic	JJ
areas	NNS
,	,
and	CC
increased	VBD
pulmonary	JJ
arterial	JJ
pressure	NN
(	(
PAP	NNP
)	)
.	.

Immunohistochemistry	NN
and	CC
mRNA	NN
analysis	NN
revealed	VBD
decreased	VBN
levels	NNS
of	IN
VEGF	NN
and	CC
its	PRP$
receptor	NN
,	,
which	WDT
were	VBD
inversely	RB
correlated	VBN
with	IN
PAP	NNP
and	CC
endothelial	JJ
cell	NN
apoptosis	NN
in	IN
both	CC
the	DT
micro	JJ
-	:
and	CC
macrovasculature	NN
.	.

Treatment	NN
of	IN
IPF	NNP
rats	NNS
with	IN
adenoviral	JJ
delivery	NN
of	IN
VEGF	NN
resulted	VBD
in	IN
reduced	VBN
endothelial	JJ
apoptosis	NN
,	,
increased	VBD
vascularization	NN
,	,
and	CC
improved	VBD
PAP	NNP
due	JJ
to	TO
reduced	VBN
remodeling	NN
but	CC
worsened	VBD
PF	NN
.	.

These	DT
data	NNS
show	VBP
that	IN
experimental	JJ
pulmonary	JJ
fibrosis	NN
(	(
PF	NN
)	)
leads	VBZ
to	TO
loss	NN
of	IN
the	DT
microvasculature	NN
through	IN
increased	VBN
apoptosis	NN
and	CC
to	TO
remodeling	NN
of	IN
the	DT
pulmonary	JJ
arteries	NNS
,	,
with	IN
both	DT
processes	NNS
resulting	VBG
in	IN
PH.	NNP
As	IN
administration	NN
of	IN
VEGF	NN
ameliorated	VBD
the	DT
PH	NN
in	IN
this	DT
model	NN
but	CC
concomitantly	RB
aggravated	VBD
the	DT
fibrogenic	JJ
process	NN
,	,
VEGF-based	JJ
therapies	NNS
should	MD
be	VB
used	VBN
with	IN
caution	NN
.	.

